Clinical Trial Update: Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating abemaciclib with nivolumab in recurrent/metastatic head and neck squamous cell carcinoma that progressed after platinum therapy; stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Drugs mentioned

• Abemaciclib (abemaciclib)
• nivolumab (nivolumab)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Head and Neck Squamous Cell Carcinoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2020-12-03